BRCA1 and ovarian cancer: Although patients with a defective Brca1 respond to the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors but exhibited very little or no significant gains in an overall survival of patients [104], highlighting the need to further study the role of epigenetics in understanding and treatment of ovarian cancer.